Challenges in the Treatment of Hepatorenal Syndrome–Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes
Before 2022, hospitalized HRS-AKI patients experienced suboptimal treatment response with off-label treatments and poor survival. There remains an unmet need for safe and effective non-transplant treatments for hospitalized HRS-AKI patients in the United States.
Authors
- Rutika Raina (ORCID: https://orcid.org/0000-0002-1585-4514)
- Giuseppe Cullaro (ORCID: https://orcid.org/0000-0002-2935-0245)
- Xingyue Huang (ORCID: https://orcid.org/0000-0002-7230-499X)
- Charles Landis
- Andrew S. Allegretti (ORCID: https://orcid.org/0000-0001-9416-6623)
- Khurram Jamil (ORCID: https://orcid.org/0000-0001-9155-3513)
- Shelby Corman (ORCID: https://orcid.org/0000-0003-4606-2971)
- Nehemiah Kebede
- Patrick Edmundson
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Kimberly Brown (ORCID: https://orcid.org/0000-0002-1114-1189)
- K. Rajender Reddy
- Sneha S. Kelkar
Institutions
- Henry Ford Health System (US)
- University of California, San Francisco (US)
- Virginia Commonwealth University (US)
- University of Washington Medical Center (US)
- Massachusetts General Hospital (US)
- Open Health Systems Laboratory (US)
- University of Pennsylvania (US)
- Mallinckrodt (Ireland) (IE)
Publication Details
- Journal
- JGH Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/jgh3.70255
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Mallinckrodt Pharmaceuticals